Breaking News

After India’s protests, UK adds Covishield to list of vaccines approved for travel

The United Kingdom on Wednesday added Covishield to its approved list COVID-19 Vaccines for country travel.

In its revised guidelines, the UK said formulations of the Oxford-AstraZeneca vaccine, including Covishield, would qualify as approved vaccines. It states that the traveler must have a full course of approved vaccines at least 14 days before arrival England.

development comes a few days later India raised strong objection For non-accreditation of Covishield manufactured by Serum Institute of India, Pune based by UK. India called this a “discriminatory policy” which affected Indian citizens wishing to travel to the UK.

“Covishield’s non-recognition is a discriminatory policy and affects our citizens traveling to the UK. The Secretary of State has vigorously raised this issue with the new UK Foreign Secretary. I am told that some assurances have been given We are sure that the issue will be resolved,” Foreign Secretary Harsh Vardhan Shringla had said on Tuesday.

A vial of Covishield is located at a vaccination center in Bengaluru, India, Tuesday, September 21, 2021. (AP)

UK’s new travel rules Effective October 4, 2021. Under the new rules, the UK has replaced its current ‘traffic light’ system List of countries in red, amber and green colors based on the level of COVID-19 risk with a single ‘red’ list. India is Currently in Amber List.

Amidst the controversy, a spokesman for the British High Commission in New Delhi told Naveen Bharat Tuesday, “The UK is committed to reopening international travel as soon as possible and this announcement is another step in enabling people to travel more freely again in a safe and sustainable manner while protecting public health.” .

“We are in talks with the Indian government to explore how we can extend UK accreditation of vaccine certification to people vaccinated by a relevant public health body in India,” the spokesperson said.

Covishield, the India-made version of Oxford-AstraZeneca’s AZD-1222 formulation, is the flagship vaccine being used in India’s large-scale immunization program against SARS-CoV-2, the COVID-19 virus.

Back to top button